Drug intelligence / Profile preview

HBI-3808

Development stage: Preclinical
Lead developer: HUYABIO International, LLC.
Modality: Small Molecules
Administration: Oral

Overview

HBI-3808 is a novel, orally bioavailable small molecule developed by HUYABIO International for the treatment of post-myocardial infarction (MI) cardiac tissue repair and regeneration. It is designed as an acellular alternative to stem cell therapies, functioning by stimulating endogenous cells to promote the formation of new cardiomyocytes and inducing angiogenesis to support tissue repair. The compound is currently part of HUYABIO's cardiovascular development portfolio.

Beyond the preview

Go deeper on HBI-3808.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HBI-3808.

Explore the full profile